Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Gene Mutation Profiles of Primary Pure Red Cell Aplasia and Large Granular Lymphocytic Leukemia Associated Pure Red Cell Aplasia

Yawen Zhang, Yuemin Gong, Xiaoqing Liu, Guangsheng He, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 5676.

https://doi.org/10.1182/blood-2024-202927

Published: 2024

Journal Articles

Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD)

Yuanyuan Jin, Xuezhong Zhang, Jianyong Li, Lei Fan, Lijuan Chen

Blood (2024) 144 (Supplement 1): 7080.

https://doi.org/10.1182/blood-2024-201203

Published: 2024

Journal Articles

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Xiao Lu, Yeqin Sha, Xinyu Song, Luomengjia Dai, Ziyuan Zhou, Hanning Tang, Yi Miao, Shuchao Qin, Yi Xia, Tonglu Qiu, Lei Fan, Jianyong Li, Huayuan Zhu

Blood (2024) 144 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2024-207729

Published: 2024

Journal Articles

Combination of Geriatric Assessment and Clinical Factors to Predict the Survival of Elderly Patients with Myeloma

Yuanyuan Jin, Ruoru Liu, Jianyong Li, Lei Fan, Lijuan Chen

Blood (2024) 144 (Supplement 1): 6951.

https://doi.org/10.1182/blood-2024-204360

Published: 2024

Journal Articles

Torque Teno Viruses Infection Associated with Suboptimal Hematological Recovery of Severe Aplastic Anemia

Yuemin Gong, Yawen Zhang, Jianyong Li, Guangsheng He, Lei Fan

Blood (2024) 144 (Supplement 1): 2702.

https://doi.org/10.1182/blood-2024-202874

Published: 2024

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2024-204881

Published: 2024

Journal Articles

Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

Xiaoyan Qu, Yating Li, Zhengxu Sun, Wanting Ying, Hailing Liu, Sanmei Wang, Miao Zhong, Jianyong Li, Lei Fan

Blood (2024) 144 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2024-206525

Published: 2024

Journal Articles

Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy

Yuan Xia, Xuxing Shen, Min Shi, Na Shen, Yu Zhu, Lei Fan, Jianyong Li, Lijuan Chen

Blood (2024) 144 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2024-205126

Published: 2024

Journal Articles

Targeting the Cgas-Sting Pathway Inhibits the Progression and Enhances the Chemotherapy Efficacy of Peripheral T-Cell Lymphoma

Hui Jin, Xueying Lu, Shunan Wang, Xiao Chen, Lei Cao, Zijuan Wu, Lei Fan, Jianyong Li

Blood (2023) 142 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2023-185299

Published: 2023

Journal Articles

Extrachromosomal Circular DNA Drives the Progression of DLBCL through Activating the Sting Pathway

Zijuan Wu, Wei Zhang, Luqiao Wang, Lei Fan, Jianyong Li, Hui Jin

Blood (2023) 142 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2023-190771

Published: 2023

Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2023-188444

Published: 2023

Journal Articles

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Huayuan Zhu, Luomengjia Dai, Yeqin Sha, Xiao Lu, Siqi Qian, Tonglu Qiu, Yi Miao, Yi Xia, Shuchao Qin, Ziyuan Zhou, Wei Wu, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2023-189681

Published: 2023

Journal Articles

Significance of the Rhoa G17V Mutation Detected By Ddpcr in Diagnostic and Monitor of Angioimmunoblastic T-Cell Lymphoma

Yi Miao, Siqi Qian, Xiao Lu, Tonglu Qiu, Shuchao Qin, Yi Xia, Lei Fan, Jianyong Li, Huayuan Zhu

Blood (2023) 142 (Supplement 1): 6083.

https://doi.org/10.1182/blood-2023-182617

Published: 2023

Journal Articles

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Huayuan Zhu, Yi Xia, Yi Miao, Shuchao Qin, Wei Wu, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 6554.

https://doi.org/10.1182/blood-2023-189110

Published: 2023

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Selinexor Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes Analysis of a Multi-Center Phase II Study in China

Kaiyang Ding, Jie Ma, Xiaohui Zhang, Chunling Wang, Huang Hongming, Lixia Sheng, Hailing Liu, Lei Cao, Wei Wu, Jianyong Li, Lei Fan

Blood (2023) 142 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2023-182553

Published: 2023

Journal Articles

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Blood (2022) 140 (Supplement 1): 3609–3611.

https://doi.org/10.1182/blood-2022-158675

Published: 2022

Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Hui Shen, Jingyan Qiu, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4164–4165.

https://doi.org/10.1182/blood-2022-170815

Published: 2022

Journal Articles

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4117–4118.

https://doi.org/10.1182/blood-2022-170985

Published: 2022

Journal Articles

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, LEI Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2022) 140 (Supplement 1): 6554–6555.

https://doi.org/10.1182/blood-2022-165797

Published: 2022

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 study)

Huayuan Zhu, Li Wang, Lei Fan, Fei Li, Yulan Zhou, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 12421–12422.

https://doi.org/10.1182/blood-2022-169381

Published: 2022

NARROW

Gene Mutation Profiles of Primary Pure Red Cell Aplasia and Large Granular Lymphocytic Leukemia Associated Pure Red Cell Aplasia

Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD)

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Combination of Geriatric Assessment and Clinical Factors to Predict the Survival of Elderly Patients with Myeloma

Torque Teno Viruses Infection Associated with Suboptimal Hematological Recovery of Severe Aplastic Anemia

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy

Targeting the Cgas-Sting Pathway Inhibits the Progression and Enhances the Chemotherapy Efficacy of Peripheral T-Cell Lymphoma

Extrachromosomal Circular DNA Drives the Progression of DLBCL through Activating the Sting Pathway

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Significance of the Rhoa G17V Mutation Detected By Ddpcr in Diagnostic and Monitor of Angioimmunoblastic T-Cell Lymphoma

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

High Rates of Remission with the Initial Treatment of Oral Selinexor Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes Analysis of a Multi-Center Phase II Study in China

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 study)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only